All In Biotech

NDA 022304 · Collegium Pharm INC

Nucynta

Tapentadol Hydrochloride · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Nov 20, 2008

Approved uses

3

Original approval plus efficacy supplements

Registered trials

73

35 Phase 3, 1 recruiting

FAERS reports

31,637

29,261 serious, 20,703 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF tapentadol TABLETS Addiction, Abuse, and Misuse Because the use of tapentadol tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.1) ] . Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of tapentadol tablets, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of tapentadol tablets are essential [see Warnings and Precautions (5.2) ] . Accidental Ingestion Accidental ingestion of even one dose of tapentadol tablets, especially by...

What it is approved for

From the label in effect Feb 26, 2026.

Tapentadol tablets are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults and pediatric patients aged 6 years and older with a body weight of at least 40kg. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dose or duration [see Warnings and Precautions (5.1) ] , reserve tapentadol tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: Have not been tolerated or are not expected to be tolerated, Have not provided adequate analgesia or are not expected to provide adequate analgesia Tapentadol tablets should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate. Tapentadol tablets are an opioid analgesic indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults and pediatric patients aged 6 years and older with a body weight of at least 40 kg. ( 1 ) Limitations of Use ( 1 ) Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration ( 5.1 ), reserve tapentadol tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): Have not been tolerated or are not expected to be tolerated, Have not provided adequate analgesia or are not expected to provide adequate analgesia Tapentadol tablets should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for...

Mechanism: Tapentadol is a centrally-acting synthetic analgesic. The exact mechanism of action is unknown. Although the clinical relevance is unclear, preclinical studies have shown that tapentadol is a mu-opioid receptor (MOR) agonist and a norepinephrine reuptake inhibitor (NRI). Analgesia in animal models is derived from both of these properties.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • NUCYNTA · TAPENTADOL HYDROCHLORIDE EQ 75MG BASE · TABLET, ORAL · Prescription · TE AB
  • NUCYNTA · TAPENTADOL HYDROCHLORIDE EQ 100MG BASE · TABLET, ORAL · Prescription · TE AB
  • NUCYNTA · TAPENTADOL HYDROCHLORIDE EQ 50MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Tapentadol" as an intervention, any sponsor and status, largest first.

All 73 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death11,609
  • toxicity to various agents9,935
  • overdose5,852
  • drug abuse1,540
  • drug dependence1,058
  • drug withdrawal syndrome neonatal928
  • drug ineffective799
  • accidental overdose721
  • nausea649
  • pain637
  • fatigue401
  • intentional product misuse388

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
20081
200998
2010155
2011339
2012306
2013294
2014299
2015754
2016885
20172,381
201821,519
2019766
2020647
2021633
2022548
2023461
2024621
2025461
2026468

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nucynta (Tapentadol HCl)

2024 spending

$56.1M

Beneficiaries

9,123

53,809 claims

Per beneficiary

$6,150

$12.25 per unit

View as table
YearSpending
2020$50,695,015
2021$53,796,706
2022$57,046,571
2023$58,810,957
2024$56,108,628

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 133 on PubMed

Sponsor: Collegium Pharm INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.